Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    23340564 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: MenHibrix (Hib-MenCY-TT);   Biological: Hib conjugate vaccine (ActHIB)

Study has passed its completion date and status has not been verified in more than two years.